Background
Methods
Data sources
Study selection
Data extraction, assessment, and synthesis
Results
Parkinson disease, other Lewy body diseases and fronto-temporal dementia
Author, year of publication | Country | Setting | Design/period of study | Population characteristics | Diagnosis criteria | Prevalence | Profile of parkinsonism patients | Comments |
---|---|---|---|---|---|---|---|---|
Bower [10], 2005 | Ethiopia | Hospital | Cross-sectional 2003-2004 | 720 patients; 109 (15 · 1%) with movement disorders including 71 men; age 52 y. (13–80) | Not provided | 72/1,000 of all admissions (PD: 64/1,000) | N:52; PD:88% | Review of medical files/outpatient neurology clinic. |
Age (at onset): 57y (30–80) | ||||||||
Men: 75% | ||||||||
Akinyemi [11], 2008 | Nigeria | Hospital | Case–control 2005-2005 | 51 patients (men 37) with PD and 50 controls | UKPDS Brain Bank criteria | NA | N:51; PD: 100% | 22% patients with PD had cognitive dysfunction, with age at PD onset as sole predictor of cognitive dysfunction. |
Age (at onset): 70y (41–80) | ||||||||
Men:72% | ||||||||
Cosnett [12], 1988 | South Africa | Hospital | Cross-sectional 1979-1985 | 2638 patients | Clinical (Bradykinesia, rigidity, resting tremor and postural instability) | 5.3/1,000 | N:14; PD: 100% | Retrospective review of medical files/outpatient clinic |
Age: NA | Blacks: 1.5/1000 | |||||||
Men: NA | Indians: 12.6/1000 | |||||||
Whites: 23.1/1000 | ||||||||
Dotchin [13], 2008 | Tanzania | Community | Cross-sectional | 161,071 inhabitants | UKPDS Brain Bank criteria | Overall: 40/100,000 | N: 32; PD:100% | Prevalence is adjusted to UK population. Mean duration 5.1 y |
Men: 64/100,000 | ||||||||
women: 20/100,000 | Age (at onset): 69y (29–90) | |||||||
Men: 72% | ||||||||
Schoenberg [14], 1988 | Nigeria | Community | Cross-sectional | Black population aged 40 + 3412 participants | Clinical | Age adjusted: 67/100,000 | N: 2; PD:100% | |
Age: NA | ||||||||
Men: NA | ||||||||
USA | Community | Cross-sectional | Black population aged 40 + 3521 black participants and 5404 white participants. | Clinical | Age adjusted: | N: 12; PD: 100% | ||
Age: NA | ||||||||
Blacks: 341/100,000 | Men: NA | |||||||
Whites: 352/100,000 | ||||||||
Winkler [15], 2010 | Tanzania | Hospital | Cross-sectional | n = 8676 patients admitted (740 with neurological diseases) | UKPDS Brain Bank criteria | 1/1,000 (all patients) | N: 8; PD:37% | |
2003 | 11/1,000 (Patients with neurological diseases | |||||||
Age: ≥32 y | ||||||||
Men: 100% | ||||||||
Community | Cross-sectional | 1569 people, age 50–110 years | UKPDS Brain Bank criteria | 235/100,000 | N: 0 | None of the 18 screened-positive was confirmed as having PD. Poisson distribution used to estimate the prevalence. | ||
2003-2005 | ||||||||
Kengne [16], 2006 | Cameroon | Hospital | Cross-sectional | 4041 patients in a neurology clinic145 (3.9%) had neurodegenerative diseases | Not provided | 488/1,000 of all neurodegenerative diseases; 10.1/1,000 of all neurologic consultation | N: 41; PD 100% | 4 selected neurodegenerative brain disorders: dementia, PD, ALS, chorea |
1993-2001 | Age: 15-84 y | |||||||
Men: 73.2% | ||||||||
Lombard [17],1978 | Zimbabwe | Hospital | Cross-sectional | Total patients admitted: 83,453 blacks, 34,952 whites | Not provided | Blacks: 0.21/1,000 | N: 50 (17 blacks) | Retrospective review of medical files |
Whites: 2.83/1,000 | Age/men: NA | |||||||
Osuntokun [18], 1979 | Nigeria | Hospital | Cross-sectional | 217 patients with parkinsonism | Not provided | NA | N: 217; PD 38% | All patients evaluated by the authors |
1966-1976 | Age: median 51-70 y, | |||||||
Men:75% | ||||||||
Osuntokun [19], 1987 | Nigeria | Community | Cross-sectional | Total participants surveyed: 18,954 | Not provided | 10/100,000 | N. 2; PD 100% | Screening Questionnaire developed by author |
1985 | Age/men: NA | |||||||
Haylett [20], 2012 | South Africa | Hospital | Cross-sectional | 229 patients with PD including 163 whites (71%), 45 mixed ancestry (20%), 17 blacks (7%) and 4 Indians (2%) | UKPDS Brain Bank criteria | NA | N: 229; PD 100% | Mutation in the Parkin gene |
Age (at onset): 54 y (17–80) | Homozygous or compound heterozygous mutations: 7 patients | |||||||
Heterozygous variant: 7 | ||||||||
Men: % NA | ||||||||
Ekenze [21], 2010 | Nigeria | Hospital | Cross-sectional | 8440 admission in the medical ward; 1249 had neurological diseases (men 640) | Not specified | 21.9/1000 of al neurological admissions | N: 14 | |
2003-2007 | Age ≥ 70 y (71%) | |||||||
Men: 28.6% | ||||||||
Owolabi [22], 2010 | Nigeria | Hospital | Cross-sectional | 6282 admission in the medical ward; 980 had neurological diseases (men 586) | Clinical: any 3 out of tremor, rigidity, Akinesia/bradikinesia/postural and instability | 4.1/1,000 of all neurological admissions | N: 4 | |
2005-2007 | Age: (50–68) | |||||||
Men; 100% | ||||||||
Okubadejo [23], 2004 | Nigeria | Hospital | Case–control | 33 participants (men 25, mean age 60 y) with PD and 33 match controls | Any 3 out of tremor, rigidity, Akinesia/bradikinesia/postural and instability | NA | N: 33 | Case fatality rate was higher in PD (25% vs. 7.1%), Factors associated with increased mortality: advanced age and disease severity |
Age (at onset): 36-80y | ||||||||
Men: 75% | ||||||||
Okubadejo [24], 2005 | Nigeria | Hospital | Case–control | 28 participants (men 21, mean age 63 y) with PD and 28 match controls | Any 2 out of tremor, rigidity, Akinesia/bradikinesia/postural and instability, exclusion of other causes of parkinsonism | NA | N: 28; PD 100% | Autonomic dysfunction rate was higher in PD (61% vs. 6%), |
Age (at onset): 37-76 y | ||||||||
Men: 76% | ||||||||
Okubadejo [25], 2010 | Nigeria | Hospital | Cross-sectional | 124 participants with Parkinsonism in a neurology clinic | Any 3 of the following: tremors, rigidity, bradykinesia, and postural or gait abnormality | 15/1,000 of all neurological consultations | N: 98; PD 79% | Other causes of parkinsonism n(%): Vascular/drug induced/MSA/LBD: 9(35)/5(19)/4(15)/3(11) |
1996-2006 | ||||||||
Age (at onset): 61y Men: 76.5% | ||||||||
Keyser [26], 2010 | South Africa | Hospital | Cross-sectional | 154 patients with PD including 51 whites (35%), 45 Afrikaners (31%), 29 mixed ancestry (20%), 17 blacks (12%) and 3 Indians (2%). | UK Parkinson’s Disease UKPDS Brain Bank criteria | NA | N: 154; PD 100% | 16 sequence variants of the PINK1gene identified: 1 homozygous mutation (Y258X), 2 heterozygous missense variants (P305A and E476K), and 13 polymorphisms |
Age (at onset): 52 y | ||||||||
Men: 62% | ||||||||
Van Der Merwe [27], 2012 | South Africa | Hospital | Cross-sectional | 111 patients with early onset PD (men 71) and 286 with late onset PD (men 62%) from a movement disorder clinic | UKPDS Brain Bank criteria | NA | N: 397; PD 100% | A positive family history was associated with a younger age at onset. |
2007-2011 | Age (at onset): 57 y Men: 248 | |||||||
Femi [28], 2012 | Nigeria | Hospital | Cross-sectional | 1153 participants in 2 Neurologic clinics; 96 (men: 74) had parkinsonism | presence of at least three of the four cardinal features of tremors, rigidity, bradykinesia, and postural or gait abnormality | 69.4/1,000 of all neurological consultations | N: 96; PD (83.3%) | |
2007-2011 | ||||||||
Age: 58 y | ||||||||
Men: 63.5% | ||||||||
Cilia [29], 2012 | Ghana | Hospital | Case–control | 54 participants with PD and 46 healthy participants | UKPDS Brain Bank criteria | NA | N: 54; PD 100% | Leucine-rich repeat kinase 2 (LRRK2) gene found in no participants |
Age (at onset): 59 y (30–83) | ||||||||
Men: 61% |
Dementia
Author, year of publication | Country/setting | Design/period of study | Population characteristics | Diagnostic criteria | Incidence | Prevalence (%) | Risk factors |
---|---|---|---|---|---|---|---|
Lambo [58], 1966 | Nigeria | Retrospective/Cross-sectional, 1954-1963 | 328 participants (26% ≥60 y.) | Not provided | NA | Senile dementia*: | NA |
Hospital | |||||||
Overall: 26%, Men: 18.9% Women: 30.5% | |||||||
75 cases of dementia (21 men) | |||||||
Ben-Arie [39], 1983 | South Africa | Cross-sectional, 1982 | 139 participants aged ≥65 y. | MMSE/ICD-8 codes | NA | Any (severe) dementia 8.6% (3.6%) | NA |
Community | |||||||
Makanjuola [59], 1985 | Nigeria | Cross-sectional 1979-1982 | 51 (5.2% of new consultations); age ≥60 y. | ICD-9 codes | NA | Dementia 11.2% | NA |
Hospital | |||||||
Gureje [60], 1989 | Nigeria | Cross-sectional, 1984 | 1914 patients; | ICD- 9 codes | NA | No case of dementia | NA |
Community | |||||||
Ogunniyi [40], 1992 | Nigeria | Cross-sectional | 930 participants; age ≥40 y. (293 aged ≥65 y.); No case of dementia | DSM-III-R criteria | NA | No case of dementia | NA |
Community | |||||||
Osuntokun [61], 1994 | Nigeria, hospital Autopsy study | Cross-sectional 1986- 1987 | 111 brains autopsied including 85 patients aged ≤60 y. | Beta A4 amyloid on brain tissues | NA | Heavy/moderate/mild plaque load: 0/6.3/18.9% | NA |
Osuntokun [41], 1995 | Nigeria, community | Cross-sectional | 56 subjects (17 with dementia and 12 with AD); age ≥65 y. | Dementia –CSID | NA | APOE ϵ4 allele in dementia/AD/controls 17.6/16.7/20.5%. | NA |
AD - NINCDS-ADRDA criteria | |||||||
Osuntokun [38], 1995 | Nigeria, hospital Autopsy study | Cross-sectional | 198 brains were autopsied | senile plaque, neurofibrillary tangle, and amyloid vascular degeneration | NA | No evidence of NFT or senile plaque | NA |
1986- 1987 | Including 45 (23%) ≥65 year | ||||||
Hendrie [32], 1995 | Nigeria, community | Cross-sectional | 2494 participants, age ≥65 y., Dementia -28, AD - 18, VaD - 8. | Dementia: CSID/DSM-III-R/ICD-10/AD: NINCDS-ADRDA criteria | NA | Dementia - Overall/65-74/75-84/≥85 y: | |
1992-1993 | 2.3/0 · 9/2.7/9.6; | ||||||
AD - 1.4/0.5/1.7/5.9% | |||||||
Indianapolis-USA, community & nursing home | Cross-sectional | 2212participants, aged ≥65 y. (community) and 106 (nursing home) | Dementia: CSID/DSM-III-R/ICD-10/AD: NINCDS-ADRDA criteria | NA | Dementia Overall/65-74/75-84/≥85 y: | NA | |
1992 - 1993 | |||||||
8.2/2 · 6/11.4/32.4% | |||||||
AD -6.2/1.6/8.0/28.8% | |||||||
Ogeng'o [33], 1996 | Tanzania, hospital | Cross-sectional | 12 Non-demented subjects aged 45–83 y. | senile plaque, neurofibrillary tangle, and cerebral amyloid angiopathy | NA | Amyloid β plaques:17% | NA |
1996 | Autopsy study | ||||||
Neurofibrillary Tangles: 17%; Cerebral Amyloid angiopathy: 17% | |||||||
Kenya, hospital | Cross-sectional Autopsy study | 20 Non-demented subjects aged 45–70 y. | Senile plaque, neurofibrillary tangle, and cerebral amyloid angiopathy | NA | Amyloid β plaques: 15%; Neurofibrillary Tangles: 15%; Cerebral Amyloid angiopathy: 15% | NA | |
USA-Cleveland, Hospital | Cross-sectional/Autopsy study | 20 Non-demented subjects aged 48–84 y. | Senile plaque, neurofibrillary tangle, and cerebral amyloid angiopathy | NA | Amyloid β plaques: 20%; Neurofibrillary: 15%; Cerebral Amyloid angiopathy: 20% | NA | |
Ogunniyi [42], 1997 | Nigeria, community | Cross-sectional | 2494 participants aged >65 y screened, 28 with dementia. | Screening: CSI-D) | NA | Any/ AD/ vascular dementia - 1.1/0.7/0.3% | N A |
1992-1994 | |||||||
Dementia: DSM-III-R and ICD-10 codes | |||||||
AD: NINCDS-ADRDA | |||||||
Sayi [62], 1997 | Tanzania, hospital | Cross-sectional | 24 demented and 286 non-demented participants aged 50–89 y. | Swahili modified MMSE | NA | Prevalence of ϵ4 allele of APOE: Demented - 25%; non demented - 21% | NA |
Kenya, hospital | Cross-sectional | 22 demented and 60 non-demented participants aged ≥65 y. | Swahili modified MMSE | NA | Prevalence of ϵ4 allele of APOE: Demented - 42%, non-demented - 27% | NA | |
Baiyewu [63], 1997 | Nigeria, Nursing home | Cross-sectional | 23 participants (in a nursing home) aged 66–102 y.; 11 women | DSM-III-R/AGECAT | NA | Any dementia (AD) - 47 · 8% (26 · 1%) | NA |
1994 | |||||||
Hall [34],1998 | Nigeria, community | Case–control | 2494 participants; age ≥ 65 y.; | Screening: CSID | NA | 18 cases of possible or probable AD1.4% | age (OR = 1.15; 95% |
423 clinically assessed after screening, | |||||||
CI = 1.12-1.18) and female gender (OR = 13.9; 95% CI = 3.85-50.82) | |||||||
Dementia: DSM-III-R/ICD-10/AD: NINCDS-ADRDA | |||||||
USA–Indianapolis, community | Case–control | 2212 participants; age ≥ 65 y.; | Screening: CSID | NA | Possible/probable AD 6.2% | age, family history of dementia, education; rural residence | |
Dementia: DSM-III-R/ICD-10/AD: NINCDS-ADRDA | |||||||
351 clinically assessed after screening,; 49 (men 17) diagnosed with AD | |||||||
Uwakwe [70], 2000 | Nigeria, Hospital | Cross-sectional | 119 participants; age ≥65 y; 3 had dementia | Geriatric Mental State and/ICD-10 | NA | 2.8% | NA |
1995-1996 | |||||||
Ogunniyi [43], 2000 | Nigeria, community | Cross-sectional 1992-1994 | 2494 participants, age ≥65 y.; 28 with dementia (men: 8) including 18 with AD, 8 with vascular dementia | Screening: CSID | NA | Any dementia 2.3% | Age (OR: 1.15), female gender (13.9), living with others (OR: 0 · 06) |
Dementia: DSM-III-R/ICD-10 | |||||||
AD: NINCDS-ADRDA | AD: 1.4% | ||||||
E4 allele in AD (normal subjects) 34.2% (21.8%) | |||||||
Indianapolis-USA, community | Cross-sectional | 2212 participants, age ≥65 year; 65 with dementia including 49 with AD, 10 with vascular dementia | Screening: CSID | NA | Dementia (AD) overall/65-74/75-84/≥85 y – 8.2 (6.2)/2.62 (1.58)/ 11.4 (8.0)/32 · 4% (28.8%); | Age, rural residence, family history of dementia, education | |
Dementia: DSM-III-R/ICD-10 | |||||||
1992-1994 | |||||||
AD: NINCDS-ADRDA | |||||||
Hendrie [35], 2001 | Nigeria, community | Prospective cohort Baseline survey in 1992-1993 | 2459 participants included after the first visit; 1303 (men 461) completed the follow-up; age ≥65 y. | Screening: CSID | Dementia: 13.5/1,000 | NA | NA |
Dementia: DSM-III-R/ICD-10 | |||||||
AD: NINCDS-ADRDA | AD: 11.5/1000 | ||||||
USA-Indianapolis, community | Prospective cohort | 2147 African-Americans included after the first visit; 1321 (men 417) completed the follow-up; age ≥65 y. | Screening: CSID | Dementia (AD) | NA | NA | |
Baseline survey in 1992-1993 | |||||||
Dementia: DSM-III-R/ICD-10/AD: NINCDS-ADRDA | |||||||
32.4/1,000 (25.2/1,000) | |||||||
Baiyewu [44], 2002 | Nigeria, community | Prospective cohort baseline survey in 1992-1993 | 2487 participants; age ≥65 y.; | Screening: CSID | Conversion from CIND to dementia 16 · 1%; From CIND to normal 25 · 3% | NA | Sex |
Dementia: DSM-III-R/ICD-10 | |||||||
423 clinically assessed after screening; 152 diagnosed with CIND; 28 (men 7) with dementia, 87 followed up for 2 years. | |||||||
Perkins [36], 2002 | Ibadan-Nigeria community | Prospective, 1992-1993 | 2487 participants; age ≥65 y; | Screening: CSID | NA | 1.8% | Dementia associated with mortality |
Dementia: DSM-III-R/ICD-10 | |||||||
423clinically assessed after screening | |||||||
Indianapolis-USA, Community | Prospective Baseline survey in 1992-1993 | 2212 participants; aged ≥65 y.; | Screening: CSID | 4.9% | Dementia associated mortality (adjusted RR: 2 · 05) | ||
342 clinically assessed after screening | |||||||
Dementia: DSM-III-R/ICD-10 | |||||||
Lane [37], 2003 | Nigeria Community | Prospective 8.7 y follow up Baseline 1992-1993 | 968 participants (271 aged ≥75 y.); | Screening: CSID | NA | NA | ApoEϵ4 alleles not associated with increased mortality |
23with dementia at follow-up | |||||||
Dementia: DSM-III-R/ICD-10 | |||||||
Indianapolis-USA, Community | Prospective 9.5 y. Baseline 1992-1993 | 353 participants (17 4 aged ≥75 y.); 17 with dementia at follow-up | Screening: CSID | NA | NA | ApoEϵ4 associated with increased mortality for patient under 75 year | |
Dementia: DSM-III-R/ICD-10 | |||||||
Ogunniyi [45], 2005 | Nigeria, Community | Cross-sectional/1992- 1998 | 98 demented subjects; age ≥65 y. | Screening: CSID | NA | AD: 82% of all cases | NA |
Dementia: DSM-III-R/ICD-10 | |||||||
VaD: 11.1% of all cases | |||||||
Kengne [16], 2006 | Cameroon, | Cross sectional, | 4041 neurologic consultations | Not provided | NA | 0.4% (all neurologic admission), 19% (neurodegenerative diseases) | NA |
Hospital | 1993-2001 | ||||||
145 with neurodegenerative diseases | |||||||
16 (men 14) with dementia, mean age 67.8 y. | |||||||
Gureje [46], 2006 | Nigeria, Community | Cross-sectional, 2003-2004 | 2152 participants at baseline with a respondent rate of 74% (1904 participants). Aged 65 year or older. | adapted 10-Word Delay Recall Test (10-WDRT)10 | NA | Overall: 10.1%; | Female gender, Increasing age, alcohol |
Female: 14.6% | |||||||
Men: 7.0% | |||||||
Gureje [71], 2006 | Nigeria Community | Cross-sectional, | 2245 DNA samples, 830 had a diagnosis | Screening: CSID | NA | Any dementia (16.9% | E4 allele in AD (normal subjects) 26 · 0% (21 · 7%) |
Dementia: DSM-III-R/ICD-10 | |||||||
AD: 14.8% | |||||||
Ogunniyi [72], 2006 | Nigeria, Community | Case–control | 62 participants with AD (Men 16.1%, mean age 82 y) and 461 non demented (men 33.2%, mean age 77 y) | Screening: CSID | NA | Age (OR 1 · 07) | |
Dementia: DSM-III-R/ICD-10/AD: NINCDS-ADRDA | |||||||
Rural to age (OR 2 · 93) Hypertension (OR 0 · 33) | |||||||
Indianapolis-USA, Community | Case–control | 89 participants with AD (men 30.3%, mean age 83 y), mean age 77 y) and 381 non demented (Men 31.2%, mean age 78 y) | Screening: CSID | NA | Age (OR 1.09 | ||
Rural to age (OR 2.08) | |||||||
Dementia: DSM-III-R/ICD-10/AD: NINCDS-ADRDA | Alcohol consumption (OR 0.49) | ||||||
Uwakwe [64], 2006 | Nigeria, Community | Cross-sectional | 30 patients (men 12) with dementia and their caregivers (total 30) | Not provided | NA | N:52; | |
2003-2005 | |||||||
AD: not provided | |||||||
Men: 12 | |||||||
Ochayi [47], 2006 | Nigeria, Community | Cross-sectional 2002 | 280 participants; age ≥65 y.; | CSID | NA | Overall dementia: 6.4% | Female gender, |
Lower body mass index, age, NSAIDS | |||||||
65-74 year old: 5.2% | |||||||
18 (men 2) with dementia | ≥85 year 16%. | ||||||
Hall [48], 2006 | Nigeria, Community | Cross-sectional | 1075 participants; age ≥ 70 y. 29 (men 5) with AD, | NINCDS-ADRDA | NA | NA | Total- or LDL- cholesterol in individuals without the APOE-ϵ4 allele |
Uwakwe [73], 2009 | Nigeria, community | Cross-sectional | 914 (men 432) participants, age ≥65 y; 87 with ≥2 tests memory tests impaired | Memory impairment assessed by MMS, CISD and 10 word list immediate and delayed recall | NA | 9.9% | NA |
Guerchet [50], 2009 | Benin Community | Cross-sectional | 502 (men 156) participants, aged ≥65 y; 52 with cognitive impairment | Screening: CSI-D | NA | Cognitive impairment | Age, current depressive disorder, absence of the APOE ϵ 2 |
Overall: 10.4%; men 7.7 women 11.5% | |||||||
Dementia: DSM-IV | |||||||
AD: NINCDS-ADRDA | Dementia Overall: 2.5%, men 0.6% women 3.4% | ||||||
13 (men 1) with dementia | |||||||
Toure [67], 2009 | Senegal | Cross-sectional | 872 participants; age ≥55 y. | DSM-IV-R | NA | Overall 6.6% | Age, social isolation, history of stroke, epilepsy, family history of dementia, Parkinson’s disease |
Hospital | 2004-2005 | 58 cases of dementia | |||||
Napon [68], 2009 | Burkina Fasso | Cross-sectional | 15815 (2396) out (in) participants; age ≥15 y.; 72 (and 53 inpatients) with dementia; AD: 7; VaD: 19 cases | DSM-IV | NA | outpatients: 0.45% inpatients: 0.22% | NA |
Hospital | |||||||
Guerchet [49], 2010 | Central African Republic Community | Cross-sectional | 509 interviewed; 496 (men 218) included in final sample, age ≥65 y. | Screening: CSID | NA | Overall: 8.1%, men 2.7%, women 12.2% | NA |
2008-2009 | |||||||
Dementia: DSM-IV | |||||||
188 with cognitive impairment and 40 (men 6) with dementia (mean age 76 y.); 33 (men 3) with AD and 7 (men 2) with VaD | AD: NINCDS-ADRDA Hachinski scale, | ||||||
Republic of Congo Community | Cross-sectional | 546 interviewed; 520 (men 198) included in final sample, age ≥65 y. 148 with cognitive impairment and 35 (men 9) with dementia (mean age 79 y.); 24 (men 7) with AD and 11 (men 3) with VaD | CSID/ DSM-IV and NINCDS-ADRDA Hachinski scale | Overall: 6.7%, men 4.5%, women 8.1% | NA | ||
2008-2009 | |||||||
Chen [65], 2010 | Kenya | Cross-sectional | 100 participants; age ≥ 65 y. | CSI-D using a version in Kikuyu. | NA | Apo ϵ4 allele frequency: | NA |
Hospital | |||||||
Demented 31.3%, non-demented 32.2% | |||||||
84 controls (men 38) and 16 with dementia participants (men 7) | |||||||
Ekenze [21], 2010 | Nigeria | Cross-sectional | 8440 admissions; 1249 (men 640) with neurological diseases (age range18-83 y.); 38 (men 23) with dementia | Not specified | NA | 3% | NA |
Hospital | 2003-2007 | ||||||
Siddiqi [69], 2009 | Zambia | Cross-sectional | 443 inpatients (men 219); median age 39 y., 67 with HIV; 368 outpatients (men 168); median age 39 y., 58 with HIV; 36 with dementia | Not specified | NA | Dementia: | Dementia in HIV + patients 8 (13.8%) vs. general population 9 (2.9%) (p = 0.002) |
Overall: 4.4% | |||||||
Hospital | 2006 | ||||||
Yusuf [74], 2011 | Nigeria Community | Cross-sectional | 322 participants (men 128); mean age: 75.5 y | Screening: CSID/CERAD/SDT | NA | Dementia: 2.8% | Age |
AD: 1.9% | |||||||
VaD: 0.6% | |||||||
Dementia: DSM-IV and ICD-10 | |||||||
9 cases of dementia (men 3); mean age: 82.4 y | LBD: McKhan clinical criteria | ||||||
FTD: McKeith clinical criteria | |||||||
Gureje [51], 2011 | Nigeria, Community | Prospective Cohort Baseline 2003-2004 | 2,149 participants at baseline | 10-Word Delayed Recall | 21.80/1,000 | NA | Poor social engagement, rural residence, low economic status, female gender, age. |
Test (cut off of 18) | |||||||
1,408 at 39 months follow-up; 85 (among ≥65 y.) developed dementia | |||||||
Ogunniyi [52], 2011 | Nigeria Community | Cohort study | 1559 participants aged > 65 year without dementia a baseline. 136 (men 33) with dementia (mean age 83.1 y.) at follow-up; 255 with MCI | Dementia: DSM-III-R and ICD-10 | Dementia: 8.72/1,000/year | NA | Low BMI |
1992-2007 | MCI: 16.35/1000/year | ||||||
Ogunniy [53], 2011 | Nigeria Community | prospective cohort baseline 1992 | 2718 participants interviewed | Dementia: DSM-III-R and ICD-10 | Dementia/AD/VaD (per 1,000/year) 11.50/9.50/1.10 | NA | Higher SBP, DBP and PP |
1753 (age ≥65 y.) in the final sample | |||||||
120 (men 30) with dementia (mean age 83.8 y.); 99 with AD; 11 with VaD | |||||||
Paraïso [56], | Benin Community | Cross-sectional | 1,139 (men 523) participants; age ≥65 y.; 42 (men 13) with dementia (mean age 79 · 1 y) | Screening: CSI-D | NA | Dementia Overall 3.7% men 1.1% women: 2.5% | NA |
2011 | |||||||
2008 | |||||||
Dementia: DSM-IV | |||||||
32 with AD, 105 with CIND | |||||||
AD: NINCDS-ADRDA | AD Overall 2.8% | ||||||
VD Overall 0.8% | |||||||
VaD: NINCDS-AIREN | |||||||
Amoo [30], | Nigeria | Cross-sectional | 240,294 participants | Dementia: ICD-10 | NA | Dementia: 45/100,000 | NA |
2011 | |||||||
AD; 25 · 8/100,000 | |||||||
Hospital | 1998-2007 | VaD: 7 · 4/100,000 | |||||
108 (men 51) with dementia (mean age: 70.1); 62 (men 24) with AD; 18 (men 13) with VaD; 4 (men 2) with mixed forms; | ADNINCDS – ADRDA | ||||||
VaD: NINCDS –AIRENS | |||||||
LBD: McKeith criteria, | |||||||
FTD: Lund and Manchester Criteria | |||||||
4 (men 2) with FTD; 3 (men 0) with DLB; 13 (men 2) with unclassified dementia | |||||||
Ndiaye [31], 2011 | Senegal | Cross-sectional | 132 patients seen at a memory clinic (men 41, mean age: 67 y | Screening: “Test du Senegal”/modified HodKinson test | NA | MCI: 14.4% | NA |
Hospital | |||||||
2004-2005 | |||||||
57 with dementia; 37 with AD, 10 with VaD, 5 with FTD and 1 with LBD. | Dementia: 43.2% | ||||||
AD: 64.7% of all cases of dementia | |||||||
MCI: Petersen criteria | |||||||
Dementia: DSM-IV | |||||||
Coume [75], 2012 | Senegal | Cross-sectional | 872 (men 546) participants aged >55 y; mean age 67 · 2 y | Test du Senegal | NA | Cognitive impairment 10.8% | NA |
Hospital | 2004-2005 | 94 (men 65) with cognitive impairment (74 aged > =65 y) | |||||
Baiyewu [54]., 2012 | Nigeria | Cross-sectional/2001 and 2004 | 21 (men 4) participants with normal cognition (mean age 82.8 y.) | Screening: CSID | NA | NA | NA |
Dementia: DSM-III-R/ICD-10 | |||||||
Community | 53 (men 4) with cognitive impairment (mean age 80.9); 34 (men 6) with dementia (mean age 83.3 y) | AD: NINCDS-ADRDA | |||||
Toure [66], 2012 | Senegal | Cross-sectional | 507 participants; age ≥65 y. | Screening: Aging in Senegal Questionnaire | NA | 8.9% | advanced age (Age ≥80 y, OR 4.3, 95% CI 1.4-13), illiteracy, epilepsy, family history of dementia |
45 with dementia | DSM-IV-R | ||||||
Hospital | 2004-2005 | ||||||
Longdon [57], 2012 | Tanzania | Cross-sectional | 1198 (men 525) participants; age ≥70 y; 78 with dementia | Screening: CSI-D | NA | 6.4% | Advanced age |
Community | 2010 | ||||||
DSM-IV-R | |||||||
Onwuekwe [76], 2012 | Nigeria | Cross-sectional | 135 participants (men: 79), aged between 16–76 y | MMSE (cut off of 17 for MCI) | NA | MCI: 5.9% | |
Hospital | 2004 | ||||||
8 with MCI | |||||||
Guerchet [55], 2012 | Central African Republic, Congo | Cross-sectional | 509 interviewed; 496 (men 218) included in final sample; age ≥65 y.; 188 with cognitive impairment | Dementia: DSM-IV-R/AD: NINCDS-ADRDA | NA | Dementia: 7.4% | Hypertension, low BMI, depressive symptoms, change of residence, age (OR 2.59, 95% CI, early death of one parent, female gender |
2008-2009 | |||||||
Community | AD: 5.6% | ||||||
546 interviewed; 520 (men 198) included in final sample; age ≥65 y.; 148 with cognitive impairment | |||||||
Overall 75 (men 15) had dementia 18 with vascular dementia |
HIV-related neurocognitive impairment
Author, year of publication | Country/setting | Design/study period | Population characteristics | Diagnostic criteria | Prevalence | Risk factors | Comments |
---|---|---|---|---|---|---|---|
Belec [77], 1989 | Central African republic, Hospital | Cross-sectional 1987 | 93 HIV + participants; age and sex not specified | Not reported | HAND: 3 cases (3.2%) | NA | No neuro-imaging or neuropathological studies |
Howlet [78], 1989 | Tanzania, hospital | Cross-sectional 1985-1988 | 200 (men 129) HIV + participants; mean age: 32 y | Decline of memory and other functions | Dementia complex: 54% | NA | |
Turnbull [79], 1991 | South Africa | Cross-sectional 1982-1983 | 27 haemophilic patients with HIV infection | Battery of neuropsychological tests: Rey complex figure, Babcock story, digit span, WAIS | HAND: 4 cases (14.8%) | NA | |
Perriëns [80], 1992 | Democratic republic of Congo Hospital | Cross sectional 2008 | 104 (men 48) HIV + participants; mean age: 34.3 y.; 92 (men 53) HIV- participants; mean age 44 y 9 (men 5) HIV + with HAND | WHO operational criteria/American Academy of neurology criteria | HIV Associated |Dementia Complex. 8.7% | NA | No neuro-imaging study |
Maj [81], 1994 | Kenya Hospital | Cross sectional 1990-1991 | 65 (men 49) HIV- participants; mean age: 30 y.; 66 (men 42) asymptomatic HIV + participants; mean age 30.7; 72 (men 48) symptomatic HIV + participants; mean age: 33.2 y | ICD-10/DSM-IV | Dementia HIV- 0 Asymptomatic HIV + 0 Symptomatic HIV + 6 (%) | NA | |
Democratic republic of Congo Hospital | 85 ( men 48) HIV- participants; mean age: 33.9 y; 52 (men 33) asymptomatic HIV + participants; mean age 32.3 y.; 68 (men 35) symptomatic HIV + participants; mean age: 33.8 y | ICD-10/DSM-IV | Dementia HIV- 0 Asymptomatic HIV + 0 Symptomatic HIV + (5.9%) | NA | |||
Carson [82], 1998 | Kenya | Cross sectional | 78 (men 52) HIV + participants; mean age: 29.9 y.; 138 (men 114) HIV- participants; mean age 29.8 y. | Revised WAIS, Trails A and Trails B tests, Digit span, Delayed word and d recognition | NA | NA | No difference in neuropsychiatric test performance between HIV + and HIV- |
Hospital | 1994 | ||||||
Sebit [83], 1995 | Kenya | Cross sectional | 191 participants, 72 (men 48) symptomatic HIV + (mean age 33.2 y.), 66 (men 42) asymptomatic HIV + (mean age 30.7) and 65 (men 49) HIV- (mean age 30 y.) | WHO operational criteria/American Academy of neurology criteria | Mental disorders: | NA | No specific data for HIV associated neurocognitive disorders |
Hospital | |||||||
1990-1991 | |||||||
Symptomatic HIV + 7.1%, Asymptomatic HIV + 4.5%, HIV -0 | |||||||
Democratic republic of Congo (DRC)/Hospital | 190 participants, 68 (men 35) symptomatic HIV + (mean age 33.8 y.), 52 (men 33) asymptomatic HIV + (mean age 32.3) and 85 (men 48) HIV- (mean age: 33.9 y.) | WHO operational criteria/American Academy of neurology criteria | Mental disorders: | NA | No specific data for HIV associated neurocognitive disorders | ||
symptomatic HIV + 5.9%, asymptomatic HIV + 1.9%, HIV– 1.2% | |||||||
Sacktor [84], 2006 | Uganda, Hospital | Prospective | 23 (men 5) HIV + participants on | MSK HIV dementia scale IHDS | Baseline: Subclinical dementia 35% | NA | All participants had CD4 count ≤200 cells/mL and an IHDS ≤ 10 (suggestive of HAND) |
Cohort study | |||||||
2004-2005 | |||||||
HAART (mean age 32.8 y.) | |||||||
Re-assessment at 3 and 6 months. | |||||||
Mild dementia 61% | |||||||
At 3 (6) months: mild dementia 26% (4%) | |||||||
Sacktor [85], 2005 | Uganda, Hospital | Cross-sectional 2003-2004 | 81 HIV+; mean age: 37 y.; 100 HIV- mean age: 31.4 y; 21 had HIV dementia | IHDS (cut off ≤10), | HIV dementia: 31% | NA | |
MSK HIV dementia scale | |||||||
Modi [86], 2007 | South-Africa, Hospital | Cross-sectional | 506 HIV + (men 203) on HAART; mean age/range: 37 years 193 had HIV associated dementia | American Academy of Neurology AIDS Task force | HIV dementia: 38% | NA | 75% had CD4 below 100 cells/mm3 |
2005 | |||||||
Clifford [87], 2007 | Ethiopia, Hospital | Case–control | 73 (men 67%) HIV + participants (median age 39 y.); | IHDS | NA | NA | Quantitative neuropsychiatric tests - no difference between groups |
2004 | |||||||
87 (men 63%) HIV- participants (median age 38 y.) | |||||||
Odiase [88], 2007 | Nigeria, Hospital | case–control | 96 (men 48) symptomatic HIV + patients (mean age 33.6 y.), | FePsy computerized neuropsychological test battery | NA | NA | Severity of immune suppression predictive of cognitive decline |
2004 | |||||||
96 (men 48) asymptomatic HIV + (mean age 31.5 y.); 96 (men 48) HIV- (mean age 32.9 y.) | |||||||
Wong [89], 2007 | Uganda, Hospital | Cross-sectional | 78 (men 28) HIV + participants (mean age 37 y.); 24 (men 6) with dementia; 100 HIV – participants | MSK HIV dementia scale | HIV dementia. 31% | Age, low CD4 count associated HIV dementia | |
2003-2004 | |||||||
Robertson [90], 2007 | Uganda, Hospital | Cross-sectional | 110 (men 34) HIV + participants (WHO Stage 2/3/4, n = 21/69/20); mean age 36.7 y.; 49 on HAART | MSK HIV dementia scale | NA | NA | Pattern of neuropsychological deficits similar to that in western countries. |
2003-2004 | |||||||
100 (men 60) HIV– controls (mean age 27.5 y.) | |||||||
Salawu [91], 2008 | Nigeria, hospital | Cross-sectional | 60 HIV + (men 24), asymptomatic, naïve of HAART; mean age 32 y) | CSID | 56.7% | No correlation between CD4 count and performance on neuropsychological testing | |
60 HIV- (men 24); mean age: 30.1 y; | |||||||
34 had HIV dementia | |||||||
Singh [92], 2008 | South Africa, Hospital | Cross-sectional | 20 HIV + (men 8) participants; median age 34 y | IHDS-criteria (cut-off ≤10) | HAND: 80% | NA | CD4 < 200 cells/mm3, older than 18 years and not be delirious. |
2007 | 16 had HAND | ||||||
Säll [93], 2009 | South Africa, Hospital | Retrospective | 38 HIV + admitted to the psychiatric ward with psychiatric symptoms; mmean age 32.4 y | DSM-IV | Dementia: 32% | NA | |
1987-1997 | |||||||
12 had dementia | |||||||
Ganasen [94], 2008 | South Africa, Hospital | Cross-sectional | 474 (men 123) HIV + patients (328 blacks and 135 coloured); mean age 34 y. | HIV dementia scale | HAND: 17.1% (IHDS) and 2.3% (MMSE) | NA | |
MMSE | |||||||
Njamnshi [95], 2008 | Cameroon, Hospital | Case–control study 2006 | 204 (men 64) HIV + participants (mean age 37.2 y.); 204 (men 64) HIV- participants (mean age 37.1 y.) | IHDS-criteria (cut-off ≤10) | HAND: | NA | |
HIV+: 21.1% | |||||||
HIV-: 2.5% | |||||||
Sacktor [96], 2009 | Uganda, Hospital | Prospective cohort | 102 (men 29) HIV + never treated patients (mean age 34.2 y.) started on Stavudine-based HAART | IHDS criteria | Base line: 40% had HIV dementia (33% mild, 7% moderate) | NA | |
MSK HIV dementia scale | |||||||
2005-2007 | |||||||
Follow-up 6 months | |||||||
25 (men 15) HIV- (mean age 30.3 y.) | |||||||
At 3 months: 26%, 23% mild, 3% moderate | |||||||
At 6 months: 16% (13% mild, 3% moderate | |||||||
Njamnshi [97], 2009 | Cameroon, Hospital | Cross-sectional | 185 (men 61) HIV + participants (mean age 37 y.); 41 with possible HAND (mean age 37y.) | IHDS-criteria | HAND: 22. 2% | Advanced clinical stage, low CD4 count, and low haemoglobin levels | |
2006 | |||||||
Sacktor [98], 2009 | Uganda, | Cross-sectional | 60 HIV + never treated participants; 22 with dementia | IHDS criteria | Overall: 36.7% | HIV subtype D associated with increased risk of HIV dementia | All participants had CD4, count ≤200 cells/mL and an IHDS ≤ 10 (suggestive of HAND) |
Hospital | |||||||
2005-2007 | |||||||
MSK HIV dementia scale | |||||||
Nakasujja [99], 2010 | Uganda, | Prospective cohort | 102 HIV + (men 28); mean age: 34.2 y; 70 with cognitive impairment at baseline | IHDS (cut-off ≤10) | Base line: 68.6% | NA | |
Hospital | |||||||
2005-2007 | |||||||
neuropsychological tests and MSK HIV dementia scale | At 3 months: 36% | ||||||
At 6 months: 30% | |||||||
Kinyanda [100], 2011 | Uganda, | Cross-sectional | 618 HIV + (men 169), 83% <45 y | IHDS (cut-off ≤ 10) | 64% | ||
396 had cognitive disorders | |||||||
Hospital | 2010 | ||||||
Choi [101], 2011 | Guinea Bissau, | Case–control | 22 HIV-2 + (men 4)participants mean age for those with CD4 < 350 = 55.1 y, mean age for those with CD4 ≥ 350 = 50.3 y) | IHDS | HIV+: 22.7% (CD4 < 350 = 27%, CD4 ≥ 350 = 18%) | age (β = -0.11) | |
Hospital | |||||||
45 HIV- controls (men 1); mean age51 · 9 y) | MSK HIV dementia scale | ||||||
Control: 11% | |||||||
Birbeck [102], 2011 | Zambia,, | Cross-sectional | 496 HIV + (men 205) participants screened within 1 week of initiating ART; mean age 38.1 y) | I\HDS (cutt-off ≤ 10) | 42.1% (IHDS) | NA | Low IHDS score was associated with poor adherence to HAART |
Hospital | 2006-2007 | ||||||
MMSE (<=22) | 34.4% (zMMSE) | ||||||
IHDS administered to 440 participants. | |||||||
185 had dementia | |||||||
Joska [103], 2010 | South Africa, Hospital | Cross-sectional | 536 (men 26.7%) HIV + participants (68% blacks, 28% coloured), mean age 34 y. | HDS (cutt-off ≤ 10) | HAND: 23.5% | Age, education, diagnosed duration, post-traumatic stress disorder | IDHS not yet available by the time of the study |
Kanmogne [104], 2010 | Cameroon | Case–control | 43 (men 18) HIV- participants (mean age 33.3 y.); 44 (men 17) HIV + participants (mean age 34.9 y.); 22 with AIDs defining conditions, 34% on HAART | HIV Neurobehavioral Research Center International neuropsychological test battery | NA | NA | |
Hospital | |||||||
2008-2009 | |||||||
Lawler [105], 2010 | Botswana, | Cross-sectional | 120 (men 60) HIV + patients (mean age 37.5 y.); 97.5% on HAART; | IHDS-criteria (cut-off ≤9.5) | HAND: 38% | NA | |
2008 | 46 with HIV dementia | ||||||
Hospital | |||||||
Patel [106], 2010 | Malawi, Hospital | Cross sectional | 179 (men 63) HIV + participants (mean age 36.7 y.); Stage III/IV 90%; 134 on HAART > 6 months; | IHDS-criteria (cut-off ≤10) | HAD | Female gender, low education | |
2007 | |||||||
25 (men 14) with HIV dementia | |||||||
Overall: 14% | |||||||
Men: 22.2% | |||||||
Women: 9.5% | |||||||
Siddiqi [69], 2009 | Zambia | Cross-sectional | 443 (men 219) inpatients (median age 39 y., 67 HIV+); 368 (men 168) outpatients (median age 39 y., 58 HIV+); Overall 36 cases of dementia | Not specified | NA | HIV+: 10.4% | HIV + patient had a higher frequency of dementia and had dementia at younger age |
Hospital | |||||||
HIV-: 3.3% | |||||||
Ekenze [21], 2010 | Nigeria, Hospital | Cross-sectional | 8440 admissions; 1249 (men 640) with neurological diseases (mean age 45 y.); 44 (men 18) with AIDS dementia complex | Not specified | AIDS dementia complex: 3.5% of all neurological admission | NA | |
2003-2007 | |||||||
Holguin [107], 2011 | Zambia, Hospital | Case–control | 57 (men 30) HIV- participants (mean age 28 y.); 83 (men 32) HIV + (mean age 34 y.) including 54 naïve of HAART | IHDS (cut-off ≤ 10) | HAND = 22% among HIV + naïve of ARV | NA | |
Color Trails Test 1 and | |||||||
2008 | 2, Grooved pegboard Test, and Time Gait Test | ||||||
Joska [108], 2011 | South Africa, Hospital | Case–control | 94 (men 36) HIV- participants (mean age 25.2 y); 96 (men 20) HIV + (mean age 29.8 y) | IHDS | NA | Education associated with IHDS total score | Validation study of the IHDS |
2008 | |||||||
Obiabo [109], 2011 | Nigeria, | Prospective Cohort study | 69 (men 25) HIV + participants with CD4 < 350 (mean age 36.2 y.); 30 (men 11) HIV- (mean age 36.6 y.) | CSID and FePsy computerized neuropsychological test battery | NA | NA | HAART improved neuropsychological performances after 12 months of treatment |
Hospital | |||||||
Joska [110], 2011 | South Africa Hospital | Cross-sectional | 170 (men 44) HIV + participants (mean age 29.5 y.)never treated; 43 (men 14) with HIV-dementia; 72 (men 19 with MND | AAN revised criteria | Mild neurocognitive disorder: 42.4% HIV dementia: 25.4% | Education, and male gender independent predictors of HIV-dementia | |
2008-2009 | |||||||
Robertson [111], 2011 | Malawi, | Cross sectional | 133 (men 39) never treated HIV + patients (median age 31 y.) | Not provided | MND: 8% | ||
HAD: 0% | |||||||
Hospital | |||||||
South Africa, | 167 (men 60) never treated HIV + patients (median age 34 y.) | Not provided | MND: 4% | ||||
HAD: 0% | |||||||
Hospital | |||||||
Zimbabwe, Hospital | 80 (men 31) never treated HIV + patients (median age 36 y.) | Not provided | MND: 14% | NA | 860 HIV + HAART naïve patients with CD4 count < 300 cells/mL and KI ≥70% | ||
HAD: 3% | |||||||
Robbins [112], 2011 | South Africa, | Cross-sectional | 65 (men 23) HIV + patients on HAART for ≥6 months (mean age 38.5 y) | IHDS and Xhosa-validated IHDS | HIV Associated dementia 80% | Low CD4 counts, alcohol dependency | |
Hospital | 2009-2010 | ||||||
Kwasa [113], 2012 | Kenya, | Cross sectional | 30 (men 17) HIV + patients (mean age 39 y.) | Neuropsychological test battery MMSE/IHDS (cut-off ≤10) | HAD 20% | NA | |
Hospital | 6 (men 5)with HAD | ||||||
Spies [114], 2012 | South-Africa, | Case–control | 35 HIV + without childhood trauma; mean age: 31.5 y | Neuropsychological test battery | NA | NA | Significant HIV effects for the Hopkins Verbal Learning Test (HVLT) learning and delay trials and the Halstead Category Test (HCT) |
Hospital | 48 HIV + with childhood trauma; mean age: 31.7 y | ||||||
27 HIV- without childhood trauma; mean: 25y | |||||||
20 HIV- with childhood trauma; mean age: 27 · 7 y | |||||||
All participants were women. | |||||||
Hestad [115], 2012 | Zambia, Hospital | Case–control | 38 HIV + (men 16); mean age: 28.3 y 42 HIV- (men 18); mean age: 28.9 y | Neuropsychological tests | NA | NA | HIV + individuals performance lower than that of HIV- on verbal fluency, executive function, speed of information processing, verbal episodic memory and motor function |
Berhe [116], 2012 | Ethiopia, | Cross-sectional | 347 HIV + (men 176) participants; mean age/range: 34.6 y admitted with neurological disorders | “cognitive and motor abnormalities, CT/MRI showing brain atrophy and other opportunistic infections ruled out” | HIV encephalopathy: 0.3% | NA | |
Hospital | Retrospective | ||||||
10 had dementia | |||||||
2002-2009 | |||||||
Joska [117], 2012 | South Africa, | Prospective | 166 HIV + participants assessed at baseline, 108 reassessed at one year (82 received HAART) | Neuropsychological tests | NA | Lower level of education | Improvement on neuropsychological tests for all participants at one year. |
Average Global deficit score | |||||||
Hospital | |||||||
Breuer [118], 2012 | South Africa, | Cross-sectional | 269 HIV + (men 97) participants on HAART for ≥6; months; 34% aged >40 y) | IHDS (cut-off ≤10.5) | HAND: 12% | NA | |
Hospital | |||||||
Hoare [119], 2012 | South Africa | Cross-sectional | 43 stage III HIV + (24 with at least one ϵ4 ApoE allele, men: 8, Age: 29 y and 19 without the ϵ4 ApoE allele, men: 2, Age: 28 y) | Neuropsychological test battery | NA | Performance on Hodgkin Verbal Learning Tool- Revised was poorer in the group with the ϵ4 genotype. | |
Participants with the ϵ4 genotype had more white matter injury on MRI. | |||||||
Hospital | |||||||
Oshinaike [120], 2012 | Nigeria | Case–control | 208 HIV + (men 71), mean age: 36.8 y | IHDS (cut off ≤10) | HAND by MMSE: 2.9% | Lower CD4 count | |
Hospital | 2007-2008 | ||||||
121 HIV – (men: 35), mean age:38.0 y | MMSE (cut off ≤26) | ||||||
AAN revised criteria (any value below 2SD) | |||||||
HAND by IHDS: 54.3% | |||||||
HAND by AAN: 42.3% | |||||||
Royal [121], 2012 | Nigeria, Hospital | Cross-sectional | 60 (men 23) never treated HIV + participants (mean age 34 y); | IHDS (cut off ≤10) | 28.8% HIV + individuals scored abnormally | Low CD4 count, WHO clinical stage of disease | |
56 (men 34) HIV- (mean age 29 · 4 y.); 32 had dementia | |||||||
16.0% HIV- individuals scored abnormally |
Amyotrophic lateral sclerosis and cerebellar degeneration
Author, year of publication | Country/setting | Design/year | Population characteristics | Diagnostic criteria/tools | Prevalence | Risk factors | Comments |
---|---|---|---|---|---|---|---|
Wall [130],1972 | Zimbabwe | Retrospective | 13 (men 10) consecutive patients; age 24–55 y. | Clinical (no ENMG) | NA | NA | 6 participants had sensory changes |
Hospital-based | 1967-1971 | ||||||
Osuntokun [126], 1974 | Nigeria | Retrospective | 92 patients with MND ALS 73; PMA 10, SMA 9 | ENMG/Muscle biopsy/ | 21/100,000 | NA | Mean age at onset: 39 y |
Mean duration of disease exceeded 15 y in 8% of participants | |||||||
Hospital-based | 1958 -1973 | ||||||
4 patients with ALS had poliomyelitis in childhood. | |||||||
Osuntokun [19], 1987 | Nigeria | Cross-sectional | 18954 participants (men 9282); 58% <20 y and 11% > 50 y | Screening questionnaire developed by the authors | MND: 15/100,000 | NA | |
Community-based | 1985 | ||||||
Cosnett [125], 1989 | South Africa Hospital-based | Retrospective Cases collected during 9.5 y. | 59 blacks (mean age 47.4 y.); 16 whites and 2 coloured (mean age 54 y.) 9 Indians (mean age 54 y) | Clinical and ENMG in 45% | Blacks/white & coloured/Indians (per 100,000) 0.88/2 · 7/1.4 | NA | Mean age of onset: 47 y (blacks) and 54 y (in whites and Indians) |
29% of participants not followed up. | |||||||
Ekenze [21], 2010 | Nigeria | Retrospective | 8440 admissions; 1249 (men 640) with neurological diseases, mean age 45 y.; 10 (men 4) with ALS | Not specified | 800/100,000 | NA | |
Hospital-based | 2003-2007 | ||||||
Abdulla [127], 1997 | Sudan | Retrospective: | 28 (men 17) patients with MND; 19 (men 14) with ALS | Clinical and ENMG | NA | Family history of MND in 14% | Mean age of onset: 40 y |
Hospital-based | 1993-1995 | ||||||
Kengne [16], 2006 | Cameroon | Retrospective | 4041 neurologic consultations; 145 with neurodegenerative diseases 10 (men 8) with ALS; mean age 50.9 y. | Not provided | 12% of all neurodegeneration 250/100,000 of all neurologic consultation | 4 selected degenerative brain diseases: Dementia, PD, ALS and chorea | |
Hospital-based | 1993-2001 | ||||||
Imam [131], 2004 | Nigeria | Retrospective | 16 (men 15) participants; age 16-60 y. | El Escorial diagnostic criteria for ALS, no ENMG | NA | NA | |
Hospital-based | 1980-99 | ||||||
Adam [129], 1992 | Kenya | Retrospective | 47(men 35) participants with MND; | Clinical (ENMG in 1/3 of participants) | NA | NA | Duration of disease: 5 m to 4 y. |
Hospital-based | 1978-88 | Age 13-80 y | |||||
18 had ALS | |||||||
Tekle-Haimanot [122], 1990 | Ethiopia | Cross-sectional | 60820 participants (men 29412), 59% aged < 20 y | Screening questionnaire and neurological exam | 5/100,000 | NA | A population survey of neurological diseases |
Community-based | 1986-88 | 3 (2 men) had MND | |||||
Harries [132], 1955 | Ethiopia | Case series | 2(all males) participants | Clinical (no ENMG) | NA | NA | |
Age 26 and 30 y | |||||||
Hospital-based | 1954 | ||||||
Jacquin-cotton [123], 1970 | Senegal | Retrospective | 6100 participants with neurological disorders | Clinical (No ENMG) | 290/100,000 | A study of patients with paraplegia in a neurological unit | |
Hospital-based | 1960-1969 | 18 (16 men) participants with ALS, age 25-70 y | |||||
Piquemal [124], 1982 | Ivory coast | Retrospective | 4000 participants with neurological disorders | Clinical (no ENMG) | 750/100,000 | NA | Duration of disease: 3 m to 5 y. |
Hospital-based | 1971-80 | 30 (men 22) participants had ALS, 50% aged <40 y | |||||
Collomb [133], 1968 | Senegal | Retrospective | 18 (17 men) participants with ALS, age 25-70 y | Clinical (no ENMG) | NA | NA | Duration of disease: 4 m to 13 y |
Hospital-based | 1960-68 | ||||||
Sene [128], 2004 | Senegal Hospital- | Retrospective | 33 (19 men) participants with ALS; | El Escorial | Definite ALS: 57%, | ||
Probable: 30%, Possible ALS: 9% | |||||||
Suspect ALS: 3% age at onset 14–67 y. | |||||||
(ENMG in half of the patients) | |||||||
based | 1999-2000 | Duration of disease: 6 m to 5 y. |
Huntington disease
Author, year of publication | Country | Setting | Design/year of the study | Population characteristics | Diagnostic tool/criteria | Prevalence |
---|---|---|---|---|---|---|
Hayden [141], 1977 | South Africa | Community | Cross-sectional | 26 cases (men 11); age 12–68 y. | Clinical | 3.5/100,000 |
Samuels [147], 1978 | Zimbabwe | Community | Case series | 1 family of HD | Clinical | NA |
4 cases (men 2) age 14–26 y. | ||||||
Glass [148], 1979 | South Africa | Community | Case series | 2 cases of HD (men 1) age 42-52 | Clinical | NA |
Hayden [142], 1980 | South Africa | Community/hospital | Cross-sectional, | 481 cases (m en 241) of whom 153 (m en 69) alive by the time of the study | Clinical | Overall: 0.65/100,000, Whites: 2.22/100,000, Mixed ancestry: 2.17/100,000, Blacks: 0 · 01/100,000 |
Scrimgeour [149], 1981 | Tanzania | Community | Case series | 11 cases, aged 25–80 y. | Clinical | NA |
Hayden [143], 1981 | Mauritius | Hospital | Cross-sectional | 2166 persons, 6 cases of HD (men 3) | Not provided | 46/100,000 |
Hayden [144], 1981 | South Africa | Hospital | Cross-sectional/NR | 17 children (onset before 20 y.) identified during a national survey among of 219 patients | Not provided | Overall: 0.6/100,000 |
Whites: 0.37/100,000 | ||||||
Mixed ancestry: 0.89/100,000 | ||||||
Blacks: No case | ||||||
Hayden [150], 1982 | South Africa | Community/hospital | Cross-sectional | 157 (men 71) individuals investigated and 328 (women 156, only 3 negro-Africans) deceased individuals with probably HD | Not specified | Combined white and black heterozygote frequency = 6 · 7 x 100,000 |
Scrimgeour [151], 1982 | Tanzania | Hospital | Case series (National registry) | 7 patients with chorea (1 aged 80 y.) and 50 potential patients with chorea in 23 families | Not specified | NA |
Mean age at onset: 36 y. | ||||||
Aiyesimoju [145], 1984 | Nigeria | Hospital | Cross sectional 1957-1982 | 2.1 million patients admitted to the hospital. | Not specified | HD: 0.2/100,000 |
4 cases (men 3) of HD aged 24–50 y at diagnosis. | ||||||
Stephany [146], 1984 | Senegal | Hospital | Cross sectional | 12370 patients seen in a neurologic clinic; 3 (men 2) with HD; age 31–64 y. | Family history | 24.2/100,000 |
All patients had movement disorders and neuropsychiatric features | ||||||
1960-1980 | ||||||
Joubert [136], 1988 | South Africa | Community/hospital | Cross-sectional 1983-1986 | 8 cases in hospital setting (n = 6. all men) and at home (n = 2); | Clinical/genetic testing/screening for Wilson disease | NA |
Age at onset: 8–47 y. | ||||||
Age at diagnosis: 13–50 y. | ||||||
Scrimgeour [152], 1992 | Zimbabwe | Hospital | Case series1991 | 11 cases in a 4 generation of a single family; 2 probable cases | Clinical | 0.5/100,000 |
Scrimgeour [153], 1995 | Sudan | Hospital | Case-report | 1 case of HD: A | Clinical/MRI | NA |
40 year old black Sudanese man | ||||||
Grunitzky [154], 1995 | Togo | Hospital | Case series | A family including 8 patients with HD and 67 at risk across 6 generations; mean age at onset: 33 y. | Not specified | NA |
Silber [137], 1998 | South Africa | Community | Case series | 5 families of HD including a total of 7 genetically confirmed cases of HD and 10 clinically suspect cases of HD | Clinical/genetic testing | NA |
Kabore [138], 2000 | Burkina-Faso | Hospital | Case series | 4 cases of HD; age at diagnosis 33–43 y. | Clinical/genetic testing | 0.04/100,000 |
Bardien [139], 2007 | South Africa | Hospital | Case series 2001-2005 | A family with HD like 2 | Clinical/genetic testing | 1 |
Total 39 family members | ||||||
13 had the disease | ||||||
Magazi [140], 2008 | South Africa | Hospital | Case series | 12 cases (men 6); age 25–52 y. | Clinical/genetic testing | NA |